Charles River Seeks Expansion In China For Outsourced Tests
This article was originally published in PharmAsia News
U.S.-based Charles River Laboratories of the United States says it plans to expand its presence in China and add people and new technologies. James Foster, CEO of the company founded by his father, said his company, which supplies genetically engineered rats and mice for research, needs to increase its own pipeline to meet the demands of drug research and a drug maker need to get products to market more rapidly. Foster said his firm would add new locations in China for outsourcing work and help accelerate that development. (Click here for more
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.